Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Amit Sanyal, MD: A Clinician’s Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Jul
22
Today In Oncology
Integrating Environmental Health Into Pediatric Cancer Care May Improve Outcomes
Emergency Department Cancer Diagnosis Associated With Higher Mortality Across 16 Cancer Types
AMP Recognizes NCI Pathologist With Award for Excellence in Molecular Diagnostics
Defining Functional High-Risk Multiple Myeloma in the Era of Quadruplet Therapy and Autologous Stem Cell Transplant
Long-Term Outcomes With SABR in Primary Kidney Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo